Clinical trial NCT00151801 - References

Multiple Sclerosis — Safety and Tolerability of Interferon-Beta-1a and Estroprogestins Association in MS Patients

Citation(s)

•   Bansil S, Lee HJ, Jindal S, Holtz CR, Cook SD
  Correlation between sex hormones and magnetic resonance imaging lesions in multiple sclerosis. Acta Neurol Scand. 1999 Feb;99(2):91-4.
•   De Cicco Nardone F, Rossiello F, Iacopino F, Benedetto MT, Cinque B, Dell'Acqua S, Sica G
  Effects of interferon-beta on steroid receptors, prostaglandins and enzymatic activities in human endometrial cancer. Anticancer Res. 1996 Jan-Feb;16(1):161-9.
•   Hawkins SA, McDonnell GV
  Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry. 1999 Aug;67(2):148-52.
•   Hernán MA, Hohol MJ, Olek MJ, Spiegelman D, Ascherio A
  Oral contraceptives and the incidence of multiple sclerosis. Neurology. 2000 Sep 26;55(6):848-54.
•   Kim S, Liva SM, Dalal MA, Verity MA, Voskuhl RR
  Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis. Neurology. 1999 Apr 12;52(6):1230-8.
•   Pozzilli C, Tomassini V, Marinelli F, Paolillo A, Gasperini C, Bastianello S
  'Gender gap' in multiple sclerosis: magnetic resonance imaging evidence. Eur J Neurol. 2003 Jan;10(1):95-7.
•   Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis
  PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998 Nov 7;352(9139):1498-504. Erratum in: Lancet 1999 Feb 20;353(9153):678.
•   Zorgdrager A, De Keyser J
  Menstrually related worsening of symptoms in multiple sclerosis. J Neurol Sci. 1997 Jul;149(1):95-7.

Safety and Tolerability of Oral Two-Doses Estroprogestins Associated With Interferon-Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Details for clinical trial NCT00151801